Form 4: Teladoc Director Salka Granted 48,638 RSUs

Teladoc Health, Inc. Director Susan R. Salka was granted 48,638 restricted stock units, aligning her interests with long-term shareholder value.

Summary

• Susan R. Salka, a Director of Teladoc Health, Inc. (TDOC), was granted 48,638 Restricted Stock Units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
• The grant date for these RSUs was March 30, 2026.
• The RSUs will vest over time, with one-third vesting on the first anniversary of the grant date, and the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a director's continued commitment to the company through equity ownership, aligning their interests with long-term shareholder value.

Positives

• The grant of 48,638 Restricted Stock Units to Director Susan R. Salka aligns her interests with the long-term performance of Teladoc Health, Inc.
• The structured vesting schedule encourages long-term commitment and retention of the director.

Future Outlook

The vesting schedule for the Restricted Stock Units indicates a future commitment from the director, with vesting continuing over several years post-grant date, aligning their long-term incentives with company performance.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units, are a common practice in the technology and healthcare sectors to incentivize and retain key personnel, including directors, by linking their compensation directly to the company's stock performance. This practice is standard across companies like Amwell (AMWL) and Hims & Hers Health (HIMS), which also utilize equity compensation to align management and director interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard compensation practice in the U.S. public market, comparable to practices at companies like Amwell (AMWL) and Hims & Hers Health (HIMS).
• The vesting schedule, typically over several years, is common for director equity awards, promoting long-term alignment, similar to what is seen at major tech and healthcare firms.

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through equity ownership, potentially leading to more shareholder-centric decision-making.

Next Steps

• Vesting of one-third of the Restricted Stock Units on March 30, 2027.
• Subsequent quarterly vesting of the remaining Restricted Stock Units over the following two years.

Key Dates

Recommendation

The grant of Restricted Stock Units to a director is a routine compensation event that aligns the director's interests with long-term shareholder value. While positive, it does not fundamentally alter the company's financial outlook or strategic position to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Teladoc Health, TDOC, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Form 4, Insider Transaction